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Abstract
Background: Burn patients are prone to infections which often necessitate broad antibiotic coverage. Vancomycin
is a common antibiotic after burn injury and is administered alone (V), or in combination with imipenem-cilastin
(V/IC) or piperacillin-tazobactam (V/PT). Sparse reports indicate that the combination V/PT is associated with
increased renal dysfunction. The purpose of this study was to evaluate the short-term impact of the three antibiotic
administration types on renal dysfunction.
Methods: All pediatric and adult patients admitted to our centers between 2004 and 2016 with a burn injury were
included in this retrospective review if they met the criteria of exposition to either V, V/IC, or V/PT for at least 48 h,
had normal baseline creatinine, and no pre-existing renal dysfunction. Creatinine was monitored for 7 days after
initial exposure; the absolute and relative increase was calculated, and patient renal outcomes were classified
according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria depending on creatinine increases
and estimated creatinine clearance. Secondary endpoints (demographic and clinical data, incidences of septicemia,
and renal replacement therapy) were analyzed. Antibiotic doses were modeled in logistic and linear multivariable
regression models to predict categorical KDIGO events and relative creatinine increase.
Results: Out of 1449 patients who were screened, 718 met the inclusion criteria, 246 were adults, and 472 were
children. Between the study cohorts V, V/IC, and V/PT, patient characteristics at admission were comparable. V/PT
administration was associated with a statistically higher serum creatinine, and lower creatinine clearance compared
to patients receiving V alone or V/IC in adults and children after burn injury. The incidence of KDIGO stages 1, 2,
and 3 was higher after V/PT treatment. In children, the incidence of KDIGO stage 3 following administration of V/PT
was greater than after V/IC. In adults, the incidence of renal replacement therapy was higher after V/PT compared
with V or V/IC. Multivariate modeling demonstrated that V/PT is an independent predictor of renal dysfunction.
Conclusion: Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal
dysfunction in pediatric and adult burn patients when compared to vancomycin alone or vancomycin plus
imipenem-cilastin. The mechanism of this increased nephrotoxicity remains elusive and warrants further scientific
evaluation.
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Background
Renal failure is a common complication in critically ill
patients, particularly in burn patients [1–3]. Acute kidney
injury (AKI) that is sustained alongside thermal injury
significantly worsens morbidity and mortality in pediatric
and adult patients [4, 5]. Over recent decades, the preva-
lence of multidrug-resistant organisms has been steadily
increasing [6, 7], limiting antibiotic treatment options for
affected patients and necessitating greater use of ag-
gressive therapeutic antimicrobial combinations [8].
Burn patients are particularly susceptible to infection
with multidrug-resistant organisms owing to substantial
loss of skin barrier function, wound contamination,
nosocomial exposure to pathogens, and impaired post-
burn immune function [9–12]. Bacterial infection is a
leading cause of death among burn patients [13] and is
treated with various combinations of antimicrobials.
Vancomycin (V) is a glycopeptide that inhibits cell wall
synthesis in gram-positive bacteria; its spectrum of
effectivity includes methicillin-resistant Staphylococcus
aureus [14]. Nephrotoxicity is a side effect of intraven-
ous vancomycin therapy [15]. Imipenem combined with
its co-effector cilastin (IC) is a broad-spectrum carba-
penem that is commonly used to treat burn-related
local and systemic infection caused by Pseudomonas
aeruginosa, Klebsiella, or Acinetobacter species [16].
Piperacillin, an extended-spectrum penicillin, combined
with the β-lactamase tazobactam (PT) has activity against
various gram-positive and gram-negative organisms, in-
cluding Pseudomonas and Enterobacteria [17]. Imipenem-
cilastin and piperacillin-tazobactam share a similar profile
of broad coverage, which enables a degree of interchange-
ability in burn care [18–20]. Recently, other groups
have reported that the combination of vancomycin and
piperacillin-tazobactam induces greater renal damage
in non-critically ill patients than vancomycin alone [21]
or the combination of vancomycin and cefepime [22].
Here, AKI associated with exposure to vancomycin
alone (V), vancomycin plus imipenem-cilastin (V/IC),
or vancomycin plus piperacillin-tazobactam (V/PT) was
quantified based on Kidney Disease Improving Global
Outcomes (KDIGO) criteria [23] to determine whether
any of these treatment combinations is indicated to be
favored regarding nephrotoxicity in adult and pediatric
burn patients.
Methods
Patients and study design
This study was approved by the Institutional Review
Board of the University of Texas Medical Branch (UTMB).
As per the Institutional Review Board, this retrospective
chart review of de-identified patient data was exempt from
additional consenting procedures. A cohort study was
designed based on a retrospective chart review between
the years 2004 and 2016. All consecutive patients admit-
ted to the UTMB adult burn unit and Shriners Hospitals
for Children®—Galveston pediatric burn unit were in-
cluded in the study if they met the following criteria:
admitted for acute burn injury of any size; normal age-
and sex-adjusted creatinine at admission; and receipt of
either vancomycin alone (V), vancomycin plus imipenem-
cilastin (V/IC), or vancomycin plus piperacillin-tazobactam
(V/PT) intravenously for at least 48 h of therapeutic treat-
ment. Exclusion criteria were: death upon admission or
within the first 48 h following admission; admission for
diagnosis other than burn injury; abnormal baseline cre-
atinine; pre-injury renal failure or dialysis; crossing over
between the study groups after first exposure to V, V/IC, or
V/PT; and incomplete demographic data. Upon admission,
burn size and severity were recorded on Lund and Browder
charts by the attending surgeon, and demographic data
were recorded. If necessary, adult patients were resuscitated
as guided by the Parkland formula as previously published
[24, 25]. Children were resuscitated according to the
standardized Galveston formula as previously published
[26, 27]: 5000 ml/m2 total body surface area (TBSA)
burned + 2000 ml/m2 TBSA lactated Ringer’s solution ad-
ministered in increments over the first 24 h after admission.
All patients with full-thickness burns were treated surgically
with complete burn wound excision and grafting with auto-
or homograft, depending on skin graft availability [26, 27].
In adults, V was administered identically in all study co-
horts at 1000–1500 mg every 12 h, and the dose adjusted
daily to maintain a trough of 10–15 μg/ml. In children, the
starting dose of V was 15 mg/kg every 6 h and the dose
was adjusted daily to maintain a trough of 10–15 μg/ml. In
adults, 500–1000 mg IC was administered every 6–8 h,
with a maximum daily dose of 50 mg/kg or 4 g, whichever
was lower. In children, 15–25 mg/kg IC was given
every 6 h with daily maximum doses of 2–4 g de-
pending on infection severity. In adults and adoles-
cents > 40 kg, 375–4500 mg PT was administered
every 6–8 hours with a maximum 18 g per day; children >
9 months and < 40 kg received 100 mg/kg PT every 6 h.
Cohorts and endpoints
Patients were allocated to one of the three cohorts based
on their exposure to V, V/IC, or V/PT as defined above.
Administered doses of antibiotics were recorded and
adjusted to patient body weight as the average daily dose
(D; mg/kg/day).
For up to 7 days after exposure, serum creatinine (Cr)
concentration was monitored daily (a daily average if
more than one value per day). The following were
determined: baseline concentration (CrBL; mg/dl); max-
imum concentration (Crmax = maximum value recorded
during 7 days post exposition; mg/dl); absolute increase
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(CrΔa = Crmax – CrBL ; mg/dl); and relative increase
(CrΔ% = (Crmax – CrBL)/CrBL × 100).
For the study period, patient status was classified accord-
ing to the creatinine-based KDIGO stages of acute kidney
injury [28]: 1 (≥1.5-fold serum creatinine increase, increase
by ≥ 0.3 mg/dL), 2 (≥ 2-fold serum creatinine increase), and
3 (≥ 3-fold serum creatinine increase or ≥ 4 mg/dl).
For 7 days after exposure, daily creatinine clearance
was estimated (eCrCl) according to Cr-based formulas.
For adult patients, Cockcroft Gault’s formula was used
[29]: eCrCl = (140 – age (years)) × bodyweight (kg) × 0.85
(if female)/72 × Cr (mg/dL). For children, the Léger for-
mula was used [30]: eCRCL = (0.641 × weight (kg))/Cr
(mg/dL) + (0.00131 × height2 (cm2))/Cr (mg/dL).
The following were determined: baseline eCrCl (eCrClBL;
mg/dl); minimum eCrCl (eCrClmin =minimum value re-
corded during 7 days post exposition; mg/dl); absolute de-
crease (eCrClΔa = eCrClmin – eCrClBL; mg/dl); and relative
decrease (eCrClΔ% = (eCrCrmin – eCrClBL)/eCrClBL × 100).
Demographic data, concomitant inhalation injury, and
septicemia, as well as occurrence of dialysis throughout
hospitalization, were noted.
Statistical analysis
Continuous, normally distributed data are presented as
mean ± standard deviation and were compared using one-
way analysis of variance (ANOVA). Nonparametric con-
tinuous data were analyzed using the Kruskal-Wallis test.
Dichotomous and categorical variables were analyzed using
the chi-squared test. A multiple general linear regression
model was fit to the continuous response (CrΔ%), with
average daily dose of V, IC, and PT as independent vari-
ables, while adjusting for TBSA percentage burned, age and
the presence of inhalation injury. Logistic regression ana-
lyses for KDIGO stages 1, 2, and 3 were performed based
on antibiotic doses as independent variables. We per-
formed stepwise logistic regression modeling while
selecting variables based on minimization of Akaike
Information Criterion [31]. Goodness of fit of the logis-
tic regression models was confirmed by the Hosmer-
Lemeshow test [32]. Due to the low incidence of AKI
events, adult and pediatric patients were analyzed
jointly in linear and logistic regression models. As indi-
cated, predictors and responses were transformed for better
fitting of model assumptions and the independence of
variables confirmed by correlation coefficients. In all com-
parisons, statistical significance was accepted at p < 0.05.
Results
Patient characteristics
During the study period, 1449 patients were admitted
(739 adults and 710 pediatric patients) to both centers.
Figure 1 illustrates the inclusion process into the analysis.
Data from 718 (246 adults and 472 children) patients were
evaluated. The median sampling time point was the year
2014 for V and V/IC, and 2011 for V/PT.
Characteristics of adult and pediatric patients are shown
in Table 1. The study cohorts were comparable with regard
to age, sex, TBSA burned, CRBL, and incidence of con-
comitant inhalation injury for both children and adults.
Fig. 1 Patient enrollment. CrBL baseline creatinine concentration, V vancomycin, V/IC vancomycin plus imipenem-cilastin, V/PT vancomycin
plus piperacillin-tazobactam
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Antibiotic treatment
Study subjects were exposed to antibiotic treatment at
comparable times during the course of hospitalization; 93%
of V, 98% of V/IC, and 97% of V/PT patients were exposed
during the first 24 h after admission (p = 0.45). Average
daily doses of vancomycin were comparable between co-
horts for both children and adults, regardless of adminis-
tration with IC, PT, or alone. The distribution of days of
exposure (2–5 days) was comparable between treatment
cohorts for both adults and children, with > 90% of
pediatric subjects and > 65% of adults being exposed for 4
or more days. Based on the administration schedules de-
scribed above, children received lower absolute doses of V,
IC, and PT than adults (p < 0.0001) but higher average
daily doses of V, IC, and PT per body weight (V: 50 ± 17
mg/kg/day; IC: 55 ± 21 mg/kg/day; PT: 257 ± 62 mg/kg/
day) than adult patients (V: 21 ± 6 mg/kg/day; IC: 20 ± 6
mg/kg/day; PT: 135 ± 41 mg/kg/day) (p < 0.0001).
Serum creatinine by treatment cohort
Adults
During 7 days after exposure to one of the treatments,
the average absolute creatinine increase was greater in
the V/PT group than in the V or V/IC groups (V/PT:
0.26 ± 0.62 mg/dl; V: 0.05 ± 0.10 mg/dl; V/IC: 0.06 ± 0.09
mg/dl; p < 0.001 for V/PT vs. V and p < 0.01 for V/PT vs.
V/IC; Fig. 2a). No difference was detected between V
and V/IC. The average relative increase in creatinine was
greater in the V/PT group than in the V or V/IC groups
(V/PT: 37 ± 91%; V: 8 ± 20%; V/IC: 7 ± 11%; p < 0.001 for
V/PT vs. V and p < 0.01 for V/PT vs. V/IC; Fig. 2b).
Absolute eCrCl decreased more after exposure to V/
PT than to V (V/PT: –26 ± 39 ml/min; V: –10 ± 28 ml/
min; p < 0.001; Fig. 3a). Relative eCrCl decreased further
in the V/PT group than in the V or V/IC groups (V/PT: –
17 ± 21%; V/IC: –7 ± 8%; V: 6 ± 10%; p < 0.001; Fig. 3b).
The rate of occurrence of KDIGO stage 1 was higher
in the V/PT group (15%) than in the V (2%) or V/IC
group (0%) (p < 0.001). KDIGO stage 2 was measured
more frequently in the V/PT group (7%) than in the V
(2%) or V/IC group (0%) (p < 0.05). KDIGO stage 3 of
AKI occurred more frequently after exposure to V/PT
(5%) compared to V (0%) or V/IC (0%) (p < 0.05; Fig. 4a).
The adjusted odds ratio of AKI stage 1 for V/PT vs. V/
IC was 18.4 (confidence interval 1.06–319.2).
Children
Over 7 days of exposure to one of the treatments, the
average absolute creatinine increase was greater in the
V/PT group than in the V/IC group (V/PT: 0.14 ± 0.49
mg/dl; V/IC: 0.05 ± 0.08 mg/dl; p < 0.05; Fig. 2c). No
differences were detected between V (V: 0.05 ± 0.07) and
V/IC or V and V/PT. The average relative increase in
creatinine was greater in the V/PT group than in the V/
IC group (V/PT: 26 ± 62%; V/IC: 14 ± 23%; p < 0.05;
Fig. 2d). No differences were found between V and V/IC
or V and V/PT (V: 16 ± 21%).
No differences in absolute decrease of eCrCl were
detected between the groups (Fig. 3c). Relative eCrCl de-
creased further in the V/PT group than in the V/IC group
(V/PT: –18 ± 2%; V/IC: –14 ± 18%; p < 0.05; Fig. 3d).
The occurrence of KDIGO stage 3 of AKI was higher
in the V/PT group (2%) than in the V (0%) or V/IC
group (0%) (p < 0.05; Fig. 4b). The rate of occurrence of
KDIGO stages 1 (V: 4%; V/IC: 9%; V/PT: 13%) or 2 (V:
0%; V/IC: 1%; V/PT: 5%) did not differ between the
groups. The odds ratio of AKI stage 3 for V/PT vs. V/IC
was 4.01 (confidence interval 1.05–15.4).
Secondary endpoints
As summarized in Additional file 1: Table S1, length of
hospitalization, as well as the incidence of septicemia and
mortality, were comparable between the treatment co-
horts both in adults and children. However, the incidence
of hemodialysis during the course of acute hospitalization
was significantly greater in adults treated with V/PT (3%)
than in those treated with V or V/IC (both 0%, p = 0.03).
Table 1 Patient characteristics at admission
V V/IC V/PT p value
Adults n = 112 n = 53 n = 81
Age (years) 46 ± 16 44 ± 16 41 ± 17 0.10
Sex (male:female), n 70:39 41:12 78:23 0.09
TBSA (%) 13.5 ± 15 12 ± 12 15 ± 17 0.46
Inhalation injury, n (%) 11 (10) 6 (11) 10 (10) 0.90
Cause of burn, n (%) ns
Flame 94 (84) 68 (90) 87 (88)
Scald 7 (6) 2 (2) 6 (6)
Electrical 6 (5) 5 (6) 2 (2)
Other 5 (5) 1 (2) 4 (4)
CRBL (mg/dl) 0.80 ± 0.18 0.79 ± 0.19 0.81 ± 0.19 0.96
Children n = 26 n = 268 n = 178
Age (years) 8 ± 6 7 ± 5 7 ± 6 0.62
Sex (male:female), n 17:9 165:103 114:64 0.83
TBSA (%) 32.0 ± 18 39 ± 19 40 ± 18 0.10
Inhalation injury, n (%) 3 (12) 48 (18) 19 (11) 0.10
Cause of burn, n (%) ns
Flame 13 (50) 137 (51) 105 (59)
Scald 7 (26) 102 (38) 57 (32)
Electrical 2 (8) 24 (9) 11 (6)
Other 4 (15) 5 (2) 5 (2)
CRBL (mg/dl) 0.46 ± 0.28 0.50 ± 0.22 0.50 ± 0.21 0.70
Values are shown as mean ± SD unless otherwise indicated
CRBL baseline creatinine concentration, IC imipenem-cilastin, ns not significant,
PT piperacillin-tazobactam, TBSA total body surface area burned, V vancomycin
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There was no difference between the pediatric study co-
horts regarding the use of renal replacement therapy
(RRT). Clinical data of patients who received RRT are
summarized in Table 2.
Statistical modeling
Multivariate models are summarized in Tables 3 and 4.
In a joint linear model for the entire patient cohort,
while controlling for TBSA, age, and the presence of in-
halation injury, the dose of PT had a significant linear
effect on CrΔ% (p < 0.001). In logistic regression models
of all patients combined, after stepwise elimination of
covariates, the dose of PT predicted KDIGO stage 1
(p = 0.03), 2 (p = 0.004), and 3 (p = 0.009). There were
no significant dose-dependencies for IC or V.
Discussion
We demonstrate in a large patient cohort that adult and
pediatric burn patients sustain independent short-term
renal effects of antibiotic treatment with vancomycin
plus piperacillin-tazobactam which are not present in
patients treated with combinations of imipenem-cilastin
and vancomycin or vancomycin alone.
These data are consistent with several smaller reports
and case series; studies in diabetic adults with osteomyelitis
[33] and heterogeneous non-critically ill patient populations
hypothesized that the combination of V/PT induces in-
creased incidences of nephrotoxicity [21, 34]. What is
unique about our study design is that we provide a large
body of pediatric data and provide a study design that
allows for detection of direct effects of drug exposition on
selective biomarkers and short-term clinical outcomes. In
line with relevant studies, we chose a minimum exposition
time of 48 h and an acute follow-up period of 7 days
following exposition to detect drug effects independently of
other clinical variables which could introduce variance later
in the course of burn injury and critical illness. Further, we
focused on the established and well-differentiated param-
eter of serum creatinine per the KDIGO classification to
define and detect our endpoints [35, 36].
An increase in serum creatinine is a strong indicator of
acute kidney damage in adult and pediatric patients and
correlates with acute and chronic renal dysfunction in a
graded manner [28, 37–39]. Greater elevations predict the
highest risk of morbidity and mortality [40, 41]. Even small
CrΔ% ≥ 50% (which corresponds to KDIGO stage 1) double
the probability of adverse outcomes and mortality [42]. Our
data showed in both adult and pediatric patients that the
relative and absolute creatinine increases following expos-
ition to vancomycin/piperacillin were approximately twice
Fig. 2 Adult average (a) absolute (mg/dl) and (b) relative (%) creatinine increase 7 days following exposure to V, V/IC, and V/PT. Child average (c)
absolute (mg/dl) and (d) relative (%) creatinine increase 7 days following exposure to V, V/IC, and V/PT. *p < 0.05, **p < 0.01, ***p < 0.001. IC
imipenem-cilastin, PT piperacillin-tazobactam, V vancomycin
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those observed with vancomycin/imipenem or vancomycin
alone. Accordingly, creatinine clearance was reduced after
exposure to vancomycin/piperacillin. Clinically, this corre-
sponded to a significantly increased incidence of short-term
renal failure in both adults and children, as well as in-
creased renal risk and injury in adults. The observed effects
can likely be attributed to the combination of vancomycin/
piperacillin, since the cohorts of V alone and V/IC behaved
similarly to each other, as well as in individual comparison
to vancomycin/piperacillin. Interestingly, the lower rates of
AKI in the vancomycin and vancomycin/imipenem groups
did not yield hard clinical advantages in terms of length of
hospitalization, septicemia, or mortality. While some of
these secondary endpoints tended towards statistical signifi-
cance, the overall sample size may have been insufficient to
reliably detect differences.
In our patient cohort, pediatric patients sustained higher
TBSA% burns than adults; therefore, outside of multivari-
ate modeling which reliably corrected for this difference,
we analyzed the study groups separately. Our data suggest
that the observed effects of antibiotic exposure on the
absolute creatinine increase, creatinine clearance decrease,
Fig. 3 Adult average (a) absolute (mg/dl) and (b) relative (%) decrease in eCrCl (calculated via Cockcroft-Gault) 7 days following exposure to V, V/
IC, and V/PT. Child average (c) absolute (mg/dl) and (d) relative (%) decrease in eCrCl (calculated via Léger’s formula) 7 days following exposure
to V, V/IC, and V/PT. *p < 0.05, ***p < 0.001, ****p < 0.0001. IC imipenem-cilastin, PT piperacillin-tazobactam, V vancomycin
Fig. 4 Relative rate of occurrence (%) of AKI events according to KDIGO stage 7 days following exposure to V, V/IC, and V/PT in adults (a) and children
(b). *p < 0.05, ****p < 0.0001. IC imipenem-cilastin, KDIGO Kidney Disease Improving Global Outcomes, PT piperacillin-tazobactam, V vancomycin
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and the incidence of KDIGO events are greater in the
pediatric patient population, while differences between the
drug groups appear less pronounced. Several factors may
contribute to this effect: children were exposed to higher
doses of vancomycin, piperacillin, and imipenem when
normalized to body weight, which may have caused in-
creased renal damage in itself; the significantly greater
severity of injury and associated systemic critical illness, as
well as dilution effects of creatinine due to the more
aggressive resuscitation measures taken in this group,
may have obscured the differences in creatinine in-
creases. Notwithstanding these potentially confounding
variables, the relationship between administration of vanco-
mycin/piperacillin and creatinine increase remains signifi-
cant and robust, indicating that the observed effect is not
exclusive to adults.
With regard to endpoints that surpass the 7-day study
window, there was an increased incidence of hemodialysis
after antibiotic treatment with vancomycin/piperacillin in
the adult patient population. Furthermore, all but one
patient who progressed to RRT belonged to the vanco-
mycin/piperacillin cohort. However, these results should
be interpreted with caution, as they may have been
confounded by a multitude of clinical variables during
the time after exposure to vancomycin/piperacillin.
This is, in part, supported by the fact that only less
than half of subjects who progressed to RRT were iden-
tified with a KDIGO-positive event during their initial
7-day study period
The mechanistic explanation of our findings remains
elusive; nephrotoxicity of vancomycin is thought to be
caused by oxidative stress and acute tubular necrosis [43],
which in turn can be promoted by product impurities
[15], pre-existing renal dysfunction [44], concomitant
critical illness [45], and increased doses and duration of
administration [21, 46]. Quite recent experimental data
by Luque et al [47]. elucidated the matter further by describ-
ing a distinct cast-nephropathy caused by nanospheric
intratubular vancomycin aggregates in mice and humans
(cit). Most clinical studies do not report incidences of
vancomycin-associated acute renal dysfunction of more than
5% [45, 46]. Piperacillin-tazobactam in comparison to other
β-lactam antibiotics has been associated with impaired renal
recovery by some study groups [48], and an additive detri-
mental effect on renal function in combination with vanco-
mycin has been proposed [21, 49]. It has been suggested
that piperacillin may decrease vancomycin clearance,
thus leading to increased accumulation and dose-
dependent nephrotoxicity of vancomycin [21]. How-
ever, this is unlikely to be the case, as comparable doses
of vancomycin were administered regardless of the co-
administered agent and that administration of vancomycin
itself was monitored closely by trough measurements.
Subjects with pre-existing renal conditions were ex-
cluded from this study, but it may be concluded that the
superimposition of effects of administration of vanco-
mycin/piperacillin on pre-existing acute or chronic
Table 2 Clinical characteristics of patients with RRT during hospitalization
Cohort TBSA (%) LOS (days) INH Septicemia First drug
exposure (days)
RRT begin (days) RRT duration (days) CrBL (mg/dl) CrΔ% (%) KDIGO+
Survivors
V/PT 62 105 N N 1 6 76 0.8 365 Y
V/PT 80 141 Y Y 0 40 13 0.7 18 N
V/PT 32 26 N N 0 10 2 1.01 77 Y
Non-survivors
V/IC 95 9 Y Y 1 10 1 0.9 0 N
V/PT 62 234 N N 0 8 18 0.9 422 Y
V/PT 45 15 N Y 1 10 4 0.95 21 N
V/PT 40 23 N Y 0 19 3 0.9 30 N
CrBL baseline creatinine concentration, CrΔ% relative creatinine increase, IC imipenem-cilastin, INHpresence of inhalation injury at admission, LOS length of
hospitalization (days), N no, PT piperacillin-tazobactam,KDIGO+ KDIGO stage 1,2, or 3 during 7 days following exposure, RRT renal replacementtherapy, TBSA total
body surface area burned (%), V vancomycin, Y yes
Table 3 Multivariable linear regression model of dose
dependency of continuous outcome creatinine increase
CrΔ%
Coefficients Estimate p
(Intercept) 1.5255 < 0.0001
[D] PT 0.0022 0.0002
TBSA 0.0010 0.7930
INH 0.4103 0.0379
Age –0.0057 0.1747
[D] V 0.0007 0.8655
All logistic models used stepwise variable selection based on minimization of
Akaike Information Criterion and passed the Hosmer Lemeshow test for
goodness of fit
CrΔ% relative creatinine increase (%), [D] PT average daily dose of piperacillin-
tazobactam (mg/kg/day), TBSA total body surface area burned, INH presence
of inhalation injury at admission, [D] V average daily dose of vancomycin co-
administered with PT (mg/kg/day)
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kidney injury should be avoided, especially in this at-risk
population. Furthermore, the low incidence of KDIGO
events in association with vancomycin alone confirms
other recent reports [43, 50] which estimate the nephro-
toxicity of vancomycin to be lower than commonly de-
scribed in older literature [51]. Clearly, further research,
perhaps in a reliable animal model which allows for
analysis of morphologic renal effects, is warranted to
elucidate this phenomenon further.
The clinical implications of this study may well extend
beyond pediatric and adult burn care. Given the increas-
ing body of evidence suggesting that even small in-
creases in creatinine are indicative of substantially worse
outcomes of morbidity and mortality, every effort should
be made to reduce nephrotoxicity. Our data suggest that
combination therapy of imipenem-cilastin with vanco-
mycin may be advantageous over piperacillin-tazobactam
in burn patients, which led to a change in our centers’ clin-
ical practice guidelines in light of the emerging findings of
others and this study. However, it needs to be strongly em-
phasized that replacing piperacillin with imipenem bears
great risks in itself, outside potential benefits regarding
nephrotoxicity. The increased use of carbapenems has
been linked to a substantial increase in multidrug-resistant
P. aeruginosa, A. baumanii, or S. maltophilia in various
clinical settings and is certainly a concern in burn care
[52–54]. Potential ways to mitigate both risks might be to
combine vancomycin with other antibiotics with lower
resistance-inducing potential or to seek alternatives to
high-dose systemic therapy with vancomycin altogether to
reduce nephrotoxic potential.
There are several limitations to this study that warrant
consideration. The single center, retrospective design
precludes inferences which could have been made from
a prospectively designed randomized trial. This study
focuses on the serum creatinine definition of KDIGO
classification as diuresis data was not available in a suffi-
ciently comprehensive manner to be included into the
analysis; however, this affects all treatment and age
groups equally and should therefore not skew the ana-
lysis, despite a tendency to potentially underestimate the
incidence of AKI. Furthermore, sensitivity of serum cre-
atinine alone has been reported to be sufficient in
detecting AKI and to be more precise than urinary out-
put measures. This study does not have a control group
of piperacillin monotherapy to allow for inferences to-
wards whether the observed toxicity of vancomycin/pi-
peracillin is attributable to vancomycin, piperacillin, or
both. In light of the large body of evidence that suggests
no individual toxicity of piperacillin, future studies will
need to verify the exact mechanism underlying the ob-
served phenomenon.
Adjustment for injury severity in this study was based
on age, TBSA burned, and the presence of inhalation in-
jury, as these are the most potent predictors in acute
burn injury. The lack of established scores such as IGS2
or SOFA as adjustors limits this study’s comparability
with other critical care patient collectives outside of
burn care.
The group of pediatric patients who received vanco-
mycin alone is disproportionately smaller than the other
cohorts. As the children in this trial were more severely
burned and had higher incidence of inhalation injury,
antibiotic monotherapy was less likely from a clinical
standpoint. Furthermore, evaluation of other potentially
confounding nephrotoxic agents (such as iodinated con-
trast agents, aminoglycosides, vasopressors, etc.) admin-
istered during the 7 days of monitoring was outside the
scope of this study. Because of the high degree of
standardization in all aspects of burn injury treatment at
our centers, we can assume that potential confounders
should affect all treatment cohorts equally and cannot
account for observed effects such as the significantly
greater creatinine increase averaged over all study pa-
tients. The bacteriological indication and efficacy of the
antibiotics administered in this study have been described
elsewhere [11, 55–58] and were not evaluated to maintain
focus on their side effects. Lastly, patients were treated
earlier in time with the combination of vancomycin/piper-
acillin because we discontinued this combination in favor
of vancomycin/imipenem when preliminary data became
available regarding its potential detrimental effects. While
this could in theory skew the analysis towards more
positive outcomes due to improvements in care in more
recent years, treatment and overall outcomes (such as
gross mortality) at our centers have not significantly
Table 4 Stepwise logistic regression models of dose dependency of categorical outcomes (KDIGO stages 1, 2, and 3)
KDIGO stage
1 2 3
Coefficients Estimate p Estimate p Estimate p
(Intercept) –3.9249 < 0.0001 –4.6114 < 0.0001 –4.5883 < 0.0001
[D] PT 0.0036 0.0364 0.0058 0.0039 0.0136 0.0086
[D] V – – – – –0.0585 0.1057
All logistic models used stepwise variable selection based on minimization of Akaike Information Criterion and passed the Hosmer Lemeshow test for goodness of fit
[D] PT average daily dose of piperacillin-tazobactam (mg/kg/day), [D] V average daily dose of vancomycin co-administered with PT (mg/kg/day), KDIGO Kidney
Disease Improving Global Outcomes
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changed in the median 4 years of time difference be-
tween the groups, which makes a confounding effect
unlikely. To the contrary, this unintentional “before-and-
after” design of this retrospective analysis strengthens its
results by equalizing the propensity to receive either V/PT
(before) or V/IC (after) for all patients over time and thus
preventing potential selection bias.
Conclusions
The co-administration of vancomycin and piperacillin-
tazobactam is associated with disproportionally elevated
serum creatinine and lower creatinine clearance when
compared to vancomycin alone or its combination with
imipenem-cilastin. This increase in serum creatinine is indi-
cative of increased incidence of renal dysfunction based on
the KDIGO criteria. The tradeoff between potentially de-
creased nephrotoxicity of vancomycin/impinenem-cilastin
and the risk of induction of multidrug-resistant organisms
due to the potential overuse of carbapenems remains a
clinical challenge.
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